A BILL 
To amend title XVIII of the Social Security Act to reform 
requirements with respect to direct and indirect remu-
neration under Medicare part D, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pharmacy DIR Reform 
4
To Reduce Senior Drug Costs Act’’. 
5
11:43 Jul 09, 2021
H3554
2 
•HR 3554 IH
SEC. 2. REQUIRING PHARMACY-NEGOTIATED PRICE CON-
1
CESSIONS, PAYMENT, AND FEES TO BE IN-
2
CLUDED IN NEGOTIATED PRICES AT THE 
3
4
CARE PROGRAM. 
5
Section 1860D–2(d)(1)(B) of the Social Security Act 
6
(42 U.S.C. 1395w–102(d)(1)(B)) is amended— 
7
(1) by striking ‘‘PRICES.—For purposes’’ and 
8
inserting ‘‘PRICES.— 
9
‘‘(i) IN
GENERAL.—For purposes’’; 
10
and 
11
(2) by adding at the end the following new 
12
clause: 
13
‘‘(ii) 
PRICES
NEGOTIATED
WITH 
14
PHARMACY AT POINT-OF-SALE.—For plan 
15
years beginning on or after January 1, 
16
2022, a negotiated price for a covered part 
17
D drug described in clause (i) shall include 
18
price concessions, payments, and fees nego-
19
tiated with such pharmacy as defined by 
20
the Secretary, but shall not include incen-
21
tive payments based on pharmacy perform-
22
ance paid or to be paid to such pharmacy. 
23
Such negotiated price shall be provided at 
24
the point-of-sale of such drug.’’. 
25
11:43 Jul 09, 2021
H3554
3 
•HR 3554 IH
SEC. 3. DISCLOSURE TO PHARMACY OF POST-POINT-OF- 
1
SALE PHARMACY PRICE CONCESSIONS AND 
2
INCENTIVE PAYMENTS. 
3
Section 1860D–2(d)(2) of the Social Security Act (42 
4
U.S.C. 1395w–102(d)(2)) is amended— 
5
(1) by striking ‘‘DISCLOSURE.—A PDP spon-
6
sor’’ and inserting ‘‘DISCLOSURE.— 
7
‘‘(A) TO THE SECRETARY.—A PDP spon-
8
sor’’; and 
9
(2) by adding at the end the following new sub-
10
paragraph: 
11
‘‘(B) TO PHARMACIES.— 
12
‘‘(i) IN
GENERAL.—For plan year 
13
2022 and subsequent plan years, a PDP 
14
sponsor offering a prescription drug plan 
15
and an MA organization offering an MA– 
16
PD plan shall report any pharmacy price 
17
concession or incentive payment that oc-
18
curs with respect to a pharmacy after pay-
19
ment for covered part D drugs at the 
20
point-of-sale, including by an intermediary 
21
organization with which a PDP sponsor or 
22
MA organization has contracted, to the 
23
pharmacy. 
24
‘‘(ii) TIMING.—The reporting of price 
25
concessions and incentive payments to a 
26
11:43 Jul 09, 2021
H3554
4 
•HR 3554 IH
pharmacy under clause (i) shall be made 
1
on a periodic basis (but in no case less fre-
2
quently than annually). 
3
‘‘(iii) CLAIM
LEVEL.—The reporting 
4
of price concessions and incentive pay-
5
ments to a pharmacy under clause (i) shall 
6
be at the claim level or approximated at 
7
the claim level if the price concession or in-
8
centive payment was applied at a level 
9
other than at the claim level.’’. 
10
SEC. 4. ESTABLISHMENT OF PHARMACY PERFORMANCE 
11
MEASURES UNDER MEDICARE PART D. 
12
Section 1860D–4(c) of the Social Security Act (42 
13
U.S.C. 1395w–104(c)) is amended— 
14
(1) by redesignating paragraph (6), as added by 
15
section 50354 of division E of the Bipartisan Budg-
16
et Act of 2018 (Public Law 115–123), as paragraph 
17
(7); and 
18
(2) by adding at the end the following new 
19
paragraph: 
20
‘‘(8) APPLICATION
OF
STANDARDIZED
PHAR-
21
MACY PERFORMANCE MEASURES.— 
22
‘‘(A) IN GENERAL.—A PDP sponsor and 
23
MA–PD plan that makes incentive payments to 
24
a pharmacy or receives price concessions paid 
25
11:43 Jul 09, 2021
H3554
5 
•HR 3554 IH
by a pharmacy based on performance measures 
1
shall, for the purposes of such incentive pay-
2
ments and price concessions with respect to cov-
3
ered part D drugs dispensed by such pharmacy, 
4
only use measures— 
5
‘‘(i) established or adopted by the Sec-
6
retary under subparagraph (B), as listed 
7
under clause (ii) of such subparagraph; 
8
and 
9
‘‘(ii) that are relevant to the perform-
10
ance of such pharmacy with respect to 
11
areas that the pharmacy can impact based 
12
on covered part D drugs dispensed and 
13
managed. 
14
‘‘(B) 
STANDARDIZED
PHARMACY
PER-
15
FORMANCE MEASURES.— 
16
‘‘(i) IN
GENERAL.—Notwithstanding 
17
any other provision of law, the Secretary 
18
shall establish or adopt standardized phar-
19
macy performance measures from one or 
20
more multi-stakeholder, consensus organi-
21
zations representing all pharmacy types 
22
(including specialty pharmacies) to be used 
23
by a PDP sponsor and MA–PD plan for 
24
the purposes of determining incentive pay-
25
11:43 Jul 09, 2021
H3554
6 
•HR 3554 IH
ments and price concessions described in 
1
subparagraph (A). Such measures shall be 
2
evidence-based and focus on pharmacy per-
3
formance on patient health outcomes and 
4
other areas, as determined by the Sec-
5
retary, that the pharmacy can impact 
6
based on covered part D drugs dispensed 
7
and managed. 
8
‘‘(ii) MAINTENANCE
OF
LIST.—The 
9
Secretary shall maintain a single list of 
10
measures established or adopted under this 
11
subparagraph and measures shall be evalu-
12
ated and updated on an ongoing basis 
13
through stakeholder consensus organiza-
14
tions to ensure they are transparent, 
15
achievable, and clinically meaningful. 
16
‘‘(iii) APPLICATION
TO
STAR
RAT-
17
INGS.—The Secretary shall require the de-
18
velopment of measures to apply in the star 
19
rating system under this part to assess the 
20
use of a standard set of pharmacy per-
21
formance measures by PDP sponsors and 
22
MA–PD plans. 
23
‘‘(C) SPECIALTY
PHARMACY.—For pur-
24
poses of subparagraph (B)(i), the Secretary 
25
11:43 Jul 09, 2021
H3554
7 
•HR 3554 IH
shall, not later than December 31, 2022, define 
1
the term ‘specialty pharmacy’ in consultation 
2
with relevant stakeholders. 
3
‘‘(D) EFFECTIVE DATE.—The requirement 
4
under subparagraph (A) shall take effect for 
5
plan years beginning on January 1, 2022, or 
6
such earlier date specified by the Secretary if 
7
the Secretary determines there are sufficient 
8
measures established or adopted under subpara-
9
graph (B) for the purposes of the requirement 
10
under subparagraph (A).’’. 
11
Æ 
11:43 Jul 09, 2021
H3554
